Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

“…Their median baseline variabilities of respiratory rate and tidal volume were 0.19 (IQR: 0.16–0.25) and 0.23 (0.19–0.34), respectively. While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …”

Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

Subjects: “…chronically infected patients…”

A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Thematic clouds for lectures. by Ignacio García-Espona (21395335)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Subjects:

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

Thematic cloud for posters [2013-23]. by Ignacio García-Espona (21395335)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …”

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects: